Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 11, Issue 8, Pages 633-652Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3800
Keywords
-
Funding
- US National Institutes of Health [AI-15614, AR-45584, CA-04 6934]
- VIDI grant from the Netherlands Research Fund
Ask authors/readers for more resources
Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1 beta antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1 alpha antibody are in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available